Ignite Creation Date:
2025-12-24 @ 11:40 PM
Ignite Modification Date:
2026-01-02 @ 1:23 AM
Study NCT ID:
NCT07077551
Status:
RECRUITING
Last Update Posted:
2025-07-22
First Post:
2025-06-27
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
NALIRIFOX as Second-Line Chemotherapy in Extrapulmonary High-grade Neuroendocrine Neoplasms: a Prospective, Single-center, Single-arm Trial
Sponsor:
Second Affiliated Hospital, School of Medicine, Zhejiang University
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2025-04-22
Start Date Type:
ACTUAL
Primary Completion Date:
2028-12-31
Primary Completion Date Type:
ESTIMATED
Completion Date:
2028-12-31
Completion Date Type:
ESTIMATED
First Submit Date:
2025-06-27
First Submit QC Date:
None
Study First Post Date:
2025-07-22
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-07-20
Last Update Post Date:
2025-07-22
Last Update Post Date Type:
ACTUAL